Cytotoxic Taxane Cyclodextrin Inclusion Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cytotoxin and immunotherapeutic delivery methods for breast cancer treatment are complex and inefficient, with paclitaxel formulations like ODDA-PTX requiring preformulation with Human Serum Albumin (HSA) due to insolubility in water, limiting further testing and development.
Innovation Solution
Development of an inclusion complex characterized by the formula (FX1): (A1—X1—X2—T2)m:(β-CyD)n, where A1 is a carboxylic acid group, T2 is a cytotoxic taxane drug moiety, X1 is an alkylene group, and β-CyD is water-soluble beta-cyclodextrin, forming a stable aqueous solution for improved solubility and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If paclitaxel is formulated with HSA to improve solubility and therapeutic index, then the drug becomes water-soluble with extended half-life, but the formulation process becomes complex and requires preformulation steps
Solution Approach 1:
The patent introduces cyclodextrin as an intermediary substance that forms inclusion complexes with paclitaxel. This mediator enables the hydrophobic paclitaxel to be solubilized in aqueous environments without requiring HSA preformulation, thus resolving the contradiction between achieving high therapeutic index and simplifying the formulation process
Solution Approach 2:
The patent changes the physical-chemical parameters of paclitaxel by forming inclusion complexes with cyclodextrin. This parameter change (from pure hydrophobic state to complexed state) enables water solubility while maintaining therapeutic efficacy, eliminating the need for complex HSA-based preformulation
2Reliability
If paclitaxel is derivatized with hydrophobic groups to improve targeting, then the therapeutic index increases, but the solubility in water decreases
Solution Approach 1:
The patent applies the nesting principle by placing the hydrophobic derivatized paclitaxel molecule inside the hydrophilic cyclodextrin cavity. This nested structure allows the hydrophobic drug core to maintain its targeting properties while the outer cyclodextrin layer provides water solubility, resolving the contradiction between enhanced therapeutic index and water solubility
3Ease of operation
If ODDA-PTX is complexed with HSA to achieve solubility, then the drug can be administered, but further animal testing is limited due to formulation complexity
Solution Approach 1:
The patent extracts the solubilization function from the complex HSA system and transfers it to cyclodextrin inclusion complexes. This extraction simplifies the formulation to a single-step process that maintains administrability while enabling comprehensive animal testing and clinical trials without the burden of complex preformulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inclusion complex enhances the solubility and therapeutic index of cytotoxic taxanes, allowing for targeted delivery to cancer tissues with reduced toxicity and extended half-life, facilitating comprehensive animal testing and clinical trials.
Implementation Method 1
an inclusion complex characterized by formula (FX1): (A1—X1—X2—T2)m:(β-CyD)n
Data Source
AI summary
Provided in the present disclosure are complexes and solutions demonstrating improved aqueous solubility of derivatized cytotoxic taxane drug moieties. In some other aspects, the disclosure provides methods of using such complexes and solutions for the treatment of cancer. In some further aspects, the disclosure provides combination therapies that may be suitable when used in combination with the use of the complexes disclosed herein.